Breakthrough LDL-C reduction in a patient with autosomal recessive homozygous familial hypercholesterolemia: Efficacy of evinacumab after LDL-apheresis discontinuation
Journal of Clinical Lipidology · 2026
DOI: 10.1016/j.jacl.2025.09.028 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Pablo González-Bustos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Vascular Unit Risk, Hospital Universitario Virgen de las Nieves, Granada, Spain (Drs González-Bustos and Mediavil-Gracia); Institu…. Hauptthemen laut MEDLINE: Cholesterol, LDL, Blood Component Removal, Homozygous Familial Hypercholesterolemia, Antibodies, Monoclonal. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Autosomal recessive homozygous familial hypercholesterolemia (AR-HoFH) is a severe lipid disorder leading to early-onset atherosclerotic cardiovascular disease (ASCVD) due to extreme low-density lipoprotein cholesterol (LDL-C) elevations. Despite high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors, many patients require LDL-apheresis for LDL-C control. CASE REPORT: We present the case of a male in his late fifties diagnosed with AR-HoFH, confirmed by genetic testing revealing biallelic pathogenic LDLRAP1 variations (NM_015627.2: c.928_930del/p.Gln310del, homozygous). The patient showed extreme hypercholesterolemia with an LDL-C exceeding 500 mg/dL (12.9 mmol/L) at diagnosis, despite high-intensity statins. At 39 years of age, he suffered a myocardial infarction with multivessel coronary artery disease requiring percutaneous coronary intervention. Despite escalation to rosuvastatin 40 mg daily, ezetimibe 10 mg daily, and alirocumab 150 mg every 2 weeks, LDL-C levels remained persistently elevated. In 2023, recurrent angina prompted coronary angiography, revealing in-stent restenosis in the right coronary artery (RCA) and a new critical stenosis in the left anterior descending (LAD) artery, requiring further revascularization. Given persistently high LDL-C levels averaging 171 mg/dL prior to apheresis despite maximal lipid-lowering therapy, biweekly LDL-apheresis was initiated and continued for 1 year. In December 2024, evinacumab (15 mg/kg intravenous monthly) was introduced following regulatory approval. Over the first 3 months, average LDL-C was reduced to 79.6 mg/dL, representing a 53.5% reduction compared to the mean preapheresis baseline, and permitting discontinuation of apheresis after the final session on January 3, 2025. By March 2025, LDL-C remained stable at 62 mg/dL (1.6 mmol/L), approaching but not fully meeting the
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine, Vascular Unit Risk, Hospital Universitario Virgen de las Nieves, Granada, Spain (Drs González-Bustos and Mediavil-Gracia); Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain (Drs Gonz…
- Unidad de Lípidos y Arteriosclerosis, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Hospital Universitario Reina Sofía, Córdoba, Spain (Drs Fuentes-Jiménez and Lista); CIBE…
- Nephrology, Hospital Universitario Reina Sofía, Córdoba, Spain (Dr Ojeda-López).
Zitieren
APA
González-Bustos, P., Fuentes-Jiménez, F., Delgado-Lista, J., Ojeda-López, R., & Mediavilla-García, J. D. (2026). Breakthrough LDL-C reduction in a patient with autosomal recessive homozygous familial hypercholesterolemia: Efficacy of evinacumab after LDL-apheresis discontinuation. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.09.028
Vancouver
González-Bustos P, Fuentes-Jiménez F, Delgado-Lista J, Ojeda-López R, Mediavilla-García JD. Breakthrough LDL-C reduction in a patient with autosomal recessive homozygous familial hypercholesterolemia: Efficacy of evinacumab after LDL-apheresis discontinuation. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2025.09.028
BibTeX
@article{GonzlezBustos2026,
author = {González-Bustos, Pablo and Fuentes-Jiménez, Francisco and Delgado-Lista, Javier and Ojeda-López, Raquel and Mediavilla-García, Juan Diego},
title = {Breakthrough LDL-C reduction in a patient with autosomal recessive homozygous familial hypercholesterolemia: Efficacy of evinacumab after LDL-apheresis discontinuation},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2025.09.028}
}
EUVIMED